Evercore ISI lowered the firm’s price target on Augmedix to $4.50 from $6.50 and keeps an In Line rating on the shares. The firm now sees slightly higher spending in FY24 with funding-related hiring nearly complete and incremental investment to expand in Bangladesh and optimization efforts in India, so it is revising its estimates, but it adds that the growth outlook “remains broadly intact.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AUGX:
- Augmedix Delivers 45% Revenue Growth and Expanded Gross Margins for Fourth Quarter of 2023
- AUGX Earnings this Week: How Will it Perform?
- Augmedix announces data, product enhancements for Augmedix Go
- Augmedix Announces New Positive Data and Enhancements to Its Ambient AI Product, Augmedix Go
- Augmedix to Announce Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024
